Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib vaccine in Canadian Aboriginal and non-Aboriginal infants  by Scheifele, David W. et al.
BI
c
n
D
D
a
b
c
d
e
f
g
a
A
R
R
A
A
K
H
H
C
I
S
A
1
i
v
b
d
C
R
n
I
T
A
h
0Vaccine 33 (2015) 1897–1900
Contents lists available at ScienceDirect
Vaccine
j our na l ho me page: www.elsev ier .com/ locate /vacc ine
rief  report
mmunogenicity  and  safety  of  3-dose  primary  vaccination  with
ombined  DTPa-HBV-IPV/Hib  vaccine  in  Canadian  Aboriginal  and
on-Aboriginal  infants
avid  W.  Scheifelea,b,∗, Murdo  Fergusonc,  Gerald  Predyd, Meena  Dawara,b,1,
eepak  Assudanie, Sherine  Kuriyakose f, Olivier  Van  Der  Meerenf,  Htay-Htay  Hang
Vaccine Evaluation Center, BC Children’s Hospital, Canada
University of British Columbia, Vancouver, Canada
Colchester Research Group, Truro, NS, Canada
Alberta Health, Edmonton, Alta., Canada
GlaxoSmithKline Vaccines, Bangalore, India
GlaxoSmithKline Vaccines, Wavre, Belgium
GlaxoSmithKline Vaccines, King of Prussia, PA, USA
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 9 October 2014
eceived in revised form 3 February 2015
ccepted 5 February 2015
vailable online 18 February 2015
eywords:
aemophilus inﬂuenzae b
a  b  s  t  r  a  c  t
This  study  compared  immune  responses  of healthy  Aboriginal  and  non-Aboriginal  infants  to  Haemophilus
inﬂuenzae  type  b  (Hib)  and hepatitis  B  virus (HBV)  components  of  a DTaP-HBV-IPV/Hib  combination
vaccine,  1 month  after  completing  dosing  at 2,  4  and  6 months  of age.  Of 112  infants  enrolled  in each
group,  94  Aboriginal  and  107  non-Aboriginal  infants  qualiﬁed  for the  immunogenicity  analysis.  Anti-PRP
concentrations  exceeded  the protective  minimum  (≥0.15 g/ml)  in ≥97%  of  infants  in both  groups  but
geometric  mean  concentrations  (GMCs)  were  higher  in  Aboriginal  infants  (6.12  g/ml  versus  3.51 g/ml).
All  subjects  were  seroprotected  (anti-HBs  ≥10  mIU/mL)  against  HBV,  with  groups  having  similar  GMCsepatitis B
ombination vaccine
mmunogenicity
afety
boriginal
(1797.9  versus  1544.4  mIU/mL,  Aboriginal  versus  non-Aboriginal,  respectively).  No safety  concerns  were
identiﬁed.  We  conclude  that  3-dose  primary  vaccination  with  DTaP-HBV-IPV/Hib  combination  vaccine
elicited  immune  responses  to Hib  and  HBV  components  that  were  at least  as high  in  Aboriginal  as  in
non-Aboriginal  Canadian  infants.
Clinical  Trial  Registration  NCT00753649.
©  2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
In Canada, new vaccines can be licensed without domestic clin-
cal trial data. A recent example was a hexavalent combination
accine (Infanrix hexa®, GlaxoSmithKline [GSK] Vaccines) that had
een evaluated mainly in Europe [1–7]. The studied populations
id not include Aboriginal children, who comprise about 5% of the
anadian pediatric population, mainly as First Nations members.
ecognizing the diminished immune responses of certain Aborigi-
al populations elsewhere [8–10] to the Haemophilus inﬂuenzae b
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264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
(Hib) polyribosylribitol phosphate (PRP) component of some vac-
cines and not knowing if this applied to Canadian Aboriginals, we
wished to assess anti-PRP responses to the new vaccine. Responses
to the hepatitis B virus (HBV) component were also of interest, as
the immunogenicity of this antigen in children was reduced in a
different hexavalent vaccine [11]. The study reported here provides
new, relevant data for Canadian Aboriginal families and communi-
ties.
2. Methods
This was a phase IV, open-label study (NCT00753649) with
two parallel groups, including Aboriginal infants (potentially First
Nations, Métis, and Inuit) and non-Aboriginal infants. It began as
a single center study (in Vancouver, British Columbia) but limited
enrollment of Aboriginal infants prompted extension to centers in
Edmonton, Alberta and Truro, Nova Scotia. Eligible infants were
healthy, 6–12 weeks old at study entry and born between 36 and
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1
Protocol completion rates for study groups.
Aboriginal infants Non-Aboriginal infants Total
Total number enrolled 112 112 224
Number immunized
Dose 1 112 112 224
Dose  2 109 112 221
Dose  3 106 112 218
ATPb cohort for safety 111 112 223
Attended ﬁnal visit (serology) 105a 112 217
Invalid, missing or off schedule serum sample 11 5 16
ATPb cohort for immunogenicity 94 107 201
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study participants are presented in Table 2. Groups were similar in
terms of age at study entry, gender mix  and concomitant vaccina-
tions. All Aboriginal infants were First Nations; no Métis or Inuit
infants were recruited.
Table 2
Demographic characteristics of study groups.
Characteristic Aboriginal infants Non-Aboriginal infants
All ATP cohorta All ATP cohorta
N 112 94 112 107
Age (weeks), dose 1
Mean 9.3 9.2 9.2 9.1
Minimum 6 6 6 6
Maximum 13 12 12 12
Female 62 49 52 49
Male 50 45 60 58
Race
White – – 66 63
Asian – – 17 16
African – – 2 2
Other – – 27 26
Aboriginal 112 94 – –
Concomitant vaccinationsb
PCV 7 conjugate 110 – 112 –a Withdrawals included 4 lost to follow-up, 1 relocation, 2 protocol violations.
b ATP: according-to-protocol.
2 weeks gestation. Exclusion criteria included immunosuppres-
ion, receipt of any blood products since birth or during the study,
erious chronic illness, major congenital defect, prior vaccination
r suspected allergy to any vaccine component. Informed consent
as obtained from a parent or legal guardian prior to enrolling each
nfant. Prior approval of the study was obtained from the research
thics board for each center and the participating Aboriginal com-
unities. Guidelines for research involving Aboriginal participants
ere followed [12].
Aboriginal infants were recruited at health centers serving their
ommunities, with study vaccine given by suitably trained local
taff. Non-Aboriginal infants were enrolled in Vancouver, where
ecruitment was  community-based and vaccines were given by
tudy nurses.
The study vaccine (Infanrix hexa®) contained per 0.5 ml  dose
iphtheria toxoid ≥30 IU (25 Lf), tetanus toxoid ≥40 IU (10 Lf), per-
ussis toxoid 25 g, ﬁmbrial hemagglutinin 25 g, pertactin 8 g,
ecombinant HBV surface antigen (HBs) 10 g, poliovirus type 1 –
0 D antigen units, type 2 – 8 D antigen units, type 3 – 32 D anti-
en units, PRP 10 g conjugated to tetanus toxoid 20–40 g and
luminum salts 0.82 mg.  Study vaccinations were scheduled at 2,
 and 6 months of age. The vaccine was administered intramuscu-
arly in the anterolateral thigh. Rotavirus vaccine (Rotarix®, GSK)
as offered as a courtesy at 2 and 4 months of age. Most partici-
ants also received routine 7-valent pneumococcal conjugate (all
enters) and meningococcal C conjugate (except in Nova Scotia)
accinations concurrently with the study vaccine in the opposite
high. EMLA® topical anesthetic could be given prior to venipunc-
ure. Vaccines were stored at 2–8 ◦C.
Parents were asked to report promptly to the investigator any
edically attended adverse event (MAAE) occurring within 31 days
fter vaccination and any serious adverse event (SAE) occurring
hile enrolled in the study. Parents were questioned about any
uch events at each visit.
A single blood sample (2–5 mL)  was obtained at 7 months of
ge, 30–48 days after the ﬁnal dose of study vaccine. Serum was
romptly harvested and stored frozen until tested. All serologic
ssays were performed at GSK Biologicals central laboratory or
esignated alternative, using standardized, validated procedures.
esting was limited to measurement of anti-PRP by enzyme-linked
mmunosorbent assay (ELISA) and anti-HBs by ELISA and a chemi-
uminescence immunoassay (CLIA)(Centaur, Siemens). Anti-PRP
esponses ≥0.15 g/ml were taken as the minimum protective level
13] and responses ≥1.0 g/ml as indicative of longer-term protec-
ion [14]. Anti-HBs concentrations ≥10 mIU/mL were considered
rotective [15]. The primary study outcome was the percentage
f participants with anti-PRP concentrations ≥0.15 g/ml. Sec-
ndary outcomes included the percentage of participants with
nti-PRP concentrations ≥1.0 g/ml, anti-HBs concentrations ≥10
nd ≥100 mIU/mL and the geometric mean concentration (GMC)
f anti-PRP and anti-HBs antibodies. An exploratory outcome wasthe difference in seroprotection rate and GMC  ratio between groups
for anti-PRP and anti-HBs, with 95% conﬁdence intervals. The safety
outcome was  the occurrence of MAAE and SAE.
The study was  powered to detect a decrease in the anti-PRP sero-
protection rate in Aboriginal as compared to non-Aboriginal infants
of greater than 10% (one-sided equivalence test of the difference in
proportions). Assuming an anti-PRP seroprotection rate of 95% in
the non-Aboriginal infants [6,11], a sample size of 95 subjects per
group was  needed to provide 81% power to rule out a seroprotec-
tion rate lower by ≥10% in Aboriginal versus non-Aboriginal infants
(alpha 0.025, one-sided). Allowing for a 15% drop-out rate and non-
evaluable subjects, 112 subjects were to be included in each study
group.
3. Results
Study visits occurred from September, 2008, to March, 2013.
Enrolment of non-Aboriginal infants (N = 112) was completed in
Vancouver; enrolment of Aboriginal infants (N = 112) was slower
and completed at 3 centers (center totals 88, 5 and 19). Table 1
describes protocol completion rates for each group. The protocol-
compliant cohorts for immunogenicity assessment included 94
Aboriginal and 107 non-Aboriginal infants, representing 84% and
96% of enrollees, respectively. Demographic characteristics of theMen C conjugate 93 – 112 –
Rotavirus 82 – 98 –
a According-to-protocol immunogenicity cohort.
b Based on ﬁrst doses administered.
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Table  3
Immunogenicity data following dose 3.
Parameter Aboriginal infants (% [95% CI]) Non-Aboriginal infants (% [95% CI])
Anti-PRP, N 94 107
≥0.15 g/ml 92 (97.9 [92.5, 99.7]) 106 (99.1 [94.9, 100])
≥1.00 g/ml 83 (88.3 [80.0, 94.0]) 91 (85.0 [76.9, 91.2])
GMC, g/ml 6.12 [4.50, 8.33] 3.51 [2.74, 4.49]
Anti-HBs, N 91 103
≥10  mIU/mL 91a (100 [96.0, 100]) 103a (100 [96.5, 100])
≥100 mIU/mL 88.6a (97.4 [91.5, 99.9]) 100.2a (97.3 [91.9, 99.8])
GMC  1797.9a [1375.1, 2350.7] 1544.4a [1210.4, 1970.5]
a Composite ﬁgure from CLIA and ELISA data based on multiple imputational analysis for greater completeness. CLIA results were preferred as more accurate than ELISA
in  the range 10–100 mIU/mL, but not all samples could be retested with CLIA. Correlation between ELISA and CLIA values in samples with both measurements were used to
impute  missing CLIA values.
Table 4
Medically attended adverse events (MAAE) during days 0–30 following three study
immunizations.
Aboriginal infants
(N = 112) (%)
Non-Aboriginal infants
(N = 112) (%)
At least one MAAE 26 (23.2) 19 (17.0)
[95% conﬁdence interval] [15.8, 32.1] [10.5, 25.2]
Respiratory conditions 18 (16.1) 9 (8.0)
Skin conditions 5 (4.5) 7 (6.2)
Intestinal conditions 4 (3.6) 5 (4.5)
Fever 6 (5.4) 0
Crying/irritability 1 (0.9) 2 (1.8)
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Total events 34 25
Immunogenicity data are presented in Table 3 for the according-
o-protocol (ATP) cohorts. Results for the total vaccinated cohorts
ere not appreciably different (data not presented). The GMC  val-
es were 6.12 and 3.51 g/ml for anti-PRP responses of Aboriginal
ersus non-Aboriginal infants, yielding a GMC  ratio of 1.74 (95% CI
.18, 2.57). For anti-HBs responses the corresponding GMC  values
ere 1797.9 and 1544.4 mIU/mL, yielding a ratio of 1.16 (95% CI
.83, 1.63).
Safety data were available following 327 vaccinations of Aborig-
nal infants and 336 vaccinations of non-Aboriginal infants. Rates of
AAEs that occurred within 30 days after vaccinations were higher
n Aboriginal than other infants (Table 4) but most events were
nrelated to immunization. SAE reports were limited to Aboriginal
nfants: 5 were hospitalized for infections (3) or seizures (2) and
wo others were attended as outpatients, one for seizures and one
or pyrexia. Only the latter was possibly vaccine-related, with onset
hortly after vaccination. All infants recovered.
. Discussion
This study was the ﬁrst to our knowledge to assess responses
f Canadian Aboriginal infants to Hib and HBV antigens in any
accine formulation, including the present hexavalent study vac-
ine. Despite early evidence that some Canadian native populations
ere at high risk of Hib meningitis [16], similar to Alaska Natives
17], vaccination programs for them were implemented without
tudies of immunogenicity. Likewise, northern Aboriginal com-
unities were known to have high rates of HBV infection [18]
ut vaccination programs were undertaken without speciﬁc trials.
uch studies are challenging to organize given the dispersal of the
ative populations among small, widely separated, often remote
ommunities and the necessary precautions for culturally respon-
ible research [12]. Having met  those challenges, we found that
articipating First Nations infants responded robustly to the Hib
omponent of a hexavalent DTPa combination vaccine, besting the
MC of non-Aboriginal infants. Anti-HBs responses were similarbetween groups. The reason for the greater Hib responses of the
Aboriginal infants is not known but is a welcome opposite to the
study hypothesis. Code-labeled sera were all tested at the end of
the study so testing-related bias is unlikely. Most infants received
concurrent 7-valent pneumococcal and meningococcal C conjugate
vaccinations, which did not appear to interfere with the measured
responses. Few other vaccine response data exist for this popu-
lation: First Nations and non-Aboriginal adults had similar mean
titers after receiving a pandemic (H1N1) inﬂuenza vaccine [19].
High Hib titers (≥5 g/ml) could afford greater resistance to Hib
colonization and reduce transmission to other Aboriginal infants
[20].
There were no safety concerns attributed to study vaccine
administration in either group. Aboriginal infants had more med-
ically attended AE and SAE but almost all were unrelated to
immunization, reﬂecting higher rates of various infections during
the study (Table 4).
The study had several important limitations. Concurrent recruit-
ment of non-Aboriginal infants occurred at only one center,
possibly introducing bias to comparisons, but only 21% of Aborigi-
nal participants were recruited at other centers. Fewer Aboriginal
than other infants provided a ﬁnal blood sample, mainly due to
accessioning difﬁculties in small communities. The number of
Aboriginal infants was  relatively small and limited to a sample
of First Nations, not necessarily representative of all First Nations.
Inuit and Métis infants were not available in the study communities
and may  also differ from those studied. Responses to other study
vaccine antigens were not assessed but have shown little variability
among other studied populations [1–7].
Hexavalent DTPa combination vaccine was  well tolerated and
immunogenic for Aboriginal and non-Aboriginal infants in this
study, for both antigens assessed. Additional studies of Canadian
Aboriginal populations are warranted to determine which, if any,
require evaluation of speciﬁc vaccine responses.
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